Current and Emerging Trends in Breast Cancer: HER2 + and HER2-Low An OncLive® Scientific Interchange and Workshop

This article provides a summary of data on treatment approaches for HER2-positive breast cancer presented at conferences in 2021 and offers a review of how findings may affect clinical approaches to escalating or de-escalating therapy in patients with early-stage disease, optimally sequencing HER2-targeted therapy in patients with metastatic breast cancer, and selecting HER2-targeted agents based on the burden of CNS disease.